Immunohistochemistry-Enabled Precision Medicine.

Immunohistochemistry-Enabled Precision Medicine.

Publication date: Jun 19, 2019

Immunohistochemistry (IHC) can be applied to diagnostic aspects of pathologic examination to provide aid in assignment of lineage and histologic type of cancer. Increasingly, however, IHC is widely used to provide prognostic and predictive (theranostic) information about the neoplastic disease. A refinement of theranostic application of IHC can be seen in the use of “genomic probing” where antibody staining results are directly correlated with an underlying genetic alteration in the tumor (somatic mutations) and/or the patient (germline constitution). All these aspects of IHC find their best use in guiding the oncologists in the optimal use of therapy for the patients.

Gatalica, Z., Feldman, R., Vrani’c, S., and Spetzler, D. Immunohistochemistry-Enabled Precision Medicine. 04927. 2019 Cancer Treat Res (178):

Concepts Keywords
Antibody Alteration tumor
Cancer Branches of biology
Constitution Medicine
Genetic Biomarkers
Germline Anatomical pathology
Histologic Protein methods
Immunohistochemistry Immunohistochemistry
Neoplastic Disease Personalized medicine
Precision Medicine Precision medicine
Somatic IHC
Staining
Theranostic
Tumor

Semantics

Type Source Name
gene UNIPROT BEST1
disease DOID cancer
disease MESH cancer
gene UNIPROT AICDA

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *